<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008915</url>
  </required_header>
  <id_info>
    <org_study_id>AAAP9855</org_study_id>
    <nct_id>NCT03008915</nct_id>
  </id_info>
  <brief_title>Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency</brief_title>
  <official_title>Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alpha-1 Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stony Wold-Herbert Fund, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test whether aspirin improves endothelial function in alpha-1&#xD;
      antitrypsin deficiency-associated lung disease, measured by pulmonary microvascular blood&#xD;
      flow on magnetic resonance imaging (MRI) and with apoptotic endothelial microparticles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emphysema is a common type of lung disease in patients with alpha-1 antitrypsin deficiency&#xD;
      (AATD). Emphysema refers to destruction of the fine network of air spaces and blood vessels&#xD;
      in the lung, and results in what looks like &quot;holes&quot; in the lung. Emphysema is associated with&#xD;
      an increased risk of death but currently no medications, except for replacement of alpha-1&#xD;
      antitrypsin (AAT), have been shown to treat emphysema.&#xD;
&#xD;
      The study plans to enroll subjects with alpha-1 antitrypsin deficiency-associated lung&#xD;
      disease (PiZZ phenotype) to perform a cross-over randomized controlled trial (RCT) of aspirin&#xD;
      compared to placebo to test the hypotheses that aspirin is effective in improving blood flow&#xD;
      in the lungs and reducing damage to the endothelial cells. Subjects will be randomized to&#xD;
      receive aspirin or placebo for 2 weeks. There will be a 2-week washout period, then the&#xD;
      participant will be crossed over to receive the other treatment (those who received aspirin&#xD;
      first will receive the placebo and those who received the placebo first will receive&#xD;
      aspirin).&#xD;
&#xD;
      Participants who are on alpha-1 replacement therapy who have had fewer than 2 exacerbations&#xD;
      in the last year will be asked whether they are interested in a withdrawal study. For this&#xD;
      second part of the study, eligible and willing participants will be asked to stop their&#xD;
      alpha-1 replacement therapy for 5 weeks and come in for a 4th study visit. This will allow&#xD;
      AAT levels to drop briefly to those seen in the absence of AAT augmentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Microvascular Blood Flow, Mean</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pulmonary microvascular blood flow is measured on contrast-enhanced MRI, limited to blood flow in the 2cm periphery of the lung</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Microparticles</measure>
    <time_frame>2 weeks</time_frame>
    <description>Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Microparticles</measure>
    <time_frame>5 weeks</time_frame>
    <description>Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Microvascular Blood Flow, Mean</measure>
    <time_frame>5 weeks</time_frame>
    <description>Pulmonary microvascular blood flow is measured on contrast-enhanced MRI in the peripheral 2cm of the lung.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <condition>Emphysema</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Aspirin first then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first then aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81mg aspirin taken once per day in the morning</description>
    <arm_group_label>Aspirin first then placebo</arm_group_label>
    <arm_group_label>Placebo first then aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo taken once per day in the morning</description>
    <arm_group_label>Aspirin first then placebo</arm_group_label>
    <arm_group_label>Placebo first then aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Withdrawal from alpha1 antitrypsin replacement therapy</intervention_name>
    <description>After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.</description>
    <arm_group_label>Aspirin first then placebo</arm_group_label>
    <arm_group_label>Placebo first then aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alpha-1 antitrypsin deficiency (PiZZ genotype)&#xD;
&#xD;
          -  40 years of age or older&#xD;
&#xD;
          -  Evidence of emphysema on CT scan as read by a Radiologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Platelet count &lt; 150,000/dL, history of intracranial hemorrhage or severe GI bleed,&#xD;
             use of systemic anticoagulant, physician prescribed use of antiplatelet drug&#xD;
             (including aspirin and P2Y12 receptor inhibitors), or known severe liver disease&#xD;
&#xD;
          -  Immunosuppression by use of medications (including oral prednisone), or those with&#xD;
             immunomodulatory disease (organ transplantation, autoimmune conditions or&#xD;
             actively-treated malignancy)&#xD;
&#xD;
          -  Known atrial fibrillation or left ventricular (LV) systolic heart failure&#xD;
&#xD;
          -  Contraindication to MRI, including pregnancy, weight &gt; 300 lbs (due to weight limits&#xD;
             of the machine), those with pacemakers, aneurysm clips, cochlear implants or other&#xD;
             implanted electronic devices, or severe claustrophobia;&#xD;
&#xD;
          -  Chronic renal insufficiency (estimated GFR &lt; 45 L/min/1.73 m2 or self report) due to&#xD;
             slightly increased risk of nephrogenic systemic fibrosis from gadolinium&#xD;
             administration and aspirin-related renal insufficiency&#xD;
&#xD;
          -  Exacerbation of respiratory symptoms within the previous 6 weeks, such as that&#xD;
             requiring hospitalization, oral prednisone or antibiotics to control symptoms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carrie Aaron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <disposition_first_submitted>July 30, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 7, 2020</disposition_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Carrie Aaron</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>alpha-1 antitrypsin deficiency</keyword>
  <keyword>Emphysema</keyword>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03008915/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aspirin First, Then Placebo</title>
          <description>Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks&#xD;
Aspirin: 81mg aspirin taken once per day in the morning&#xD;
Placebo: placebo taken once per day in the morning&#xD;
Withdrawal from alpha1 antitrypsin replacement therapy: After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Aspirin</title>
          <description>Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks&#xD;
Aspirin: 81mg aspirin taken once per day in the morning&#xD;
Placebo: placebo taken once per day in the morning&#xD;
Withdrawal from alpha1 antitrypsin replacement therapy: After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Baseline characteristics reported for all 15 participants in the crossover study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Former smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC ratio</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent emphysema, -950 HU</title>
          <population>1 participant withdrew before CT scan</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Microvascular Blood Flow, Mean</title>
        <description>Pulmonary microvascular blood flow is measured on contrast-enhanced MRI, limited to blood flow in the 2cm periphery of the lung</description>
        <time_frame>2 weeks</time_frame>
        <population>Due to errors in acquisition of MRI, a number of participants had uninterpretable scans. 13 participants had MRIs interpretable for PMBF on placebo, and 7 on aspirin. Altogether, there were 6 participants with paired results from the two scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Assessment on aspirin 81mg for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Assessment on placebo for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Microvascular Blood Flow, Mean</title>
          <description>Pulmonary microvascular blood flow is measured on contrast-enhanced MRI, limited to blood flow in the 2cm periphery of the lung</description>
          <population>Due to errors in acquisition of MRI, a number of participants had uninterpretable scans. 13 participants had MRIs interpretable for PMBF on placebo, and 7 on aspirin. Altogether, there were 6 participants with paired results from the two scans.</population>
          <units>mL blood/minute per 100mL lung</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="13.0"/>
                    <measurement group_id="O2" value="35.1" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between measures on aspirin and placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Paired t-test for participants with measures on both aspirin and placebo.</non_inferiority_desc>
            <p_value>0.692</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Microparticles</title>
        <description>Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.</description>
        <time_frame>2 weeks</time_frame>
        <population>Due to lab closure and technician availability, only the first 3 participants had EMPs measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Assessment on aspirin 81mg for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Assessment on placebo for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Microparticles</title>
          <description>Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.</description>
          <population>Due to lab closure and technician availability, only the first 3 participants had EMPs measured.</population>
          <units>EMPs/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD31+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="749.0" spread="231.1"/>
                    <measurement group_id="O2" value="821.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD62+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1357.3" spread="469.6"/>
                    <measurement group_id="O2" value="596" spread="287.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin V, CD31+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.0" spread="62.8"/>
                    <measurement group_id="O2" value="317.0" spread="210.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Microparticles</title>
        <description>Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.</description>
        <time_frame>5 weeks</time_frame>
        <population>Only 2 participants had EMPs measured on placebo and 2 off AAT replacement therapy, only 1 participant had EMPs measured at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Off Alpha-1 Replacement Therapy</title>
            <description>Assessment after 5 weeks off alpha-1 replacement therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Assessment on placebo for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Microparticles</title>
          <description>Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.</description>
          <population>Only 2 participants had EMPs measured on placebo and 2 off AAT replacement therapy, only 1 participant had EMPs measured at both time points.</population>
          <units>EMPs/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD31+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="996.0" spread="408.7"/>
                    <measurement group_id="O2" value="821.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD62+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3681.5" spread="3806.4"/>
                    <measurement group_id="O2" value="596.0" spread="287.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin V, CD31+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.0" spread="186.7"/>
                    <measurement group_id="O2" value="317.0" spread="210.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Microvascular Blood Flow, Mean</title>
        <description>Pulmonary microvascular blood flow is measured on contrast-enhanced MRI in the peripheral 2cm of the lung.</description>
        <time_frame>5 weeks</time_frame>
        <population>2 participants who completed the withdrawal phase had MRIs interpretable for PMBF on placebo and off AAT replacement therapy, data for the other 2 participants was uninterpretable for at least 1 of the 2 scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Off Alpha-1 Replacement Therapy</title>
            <description>Assessment after 5 weeks off alpha-1 replacement therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Assessment on placebo for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Microvascular Blood Flow, Mean</title>
          <description>Pulmonary microvascular blood flow is measured on contrast-enhanced MRI in the peripheral 2cm of the lung.</description>
          <population>2 participants who completed the withdrawal phase had MRIs interpretable for PMBF on placebo and off AAT replacement therapy, data for the other 2 participants was uninterpretable for at least 1 of the 2 scans.</population>
          <units>mL blood/minute per 100mL lung</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="2.6"/>
                    <measurement group_id="O2" value="35.1" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the course of the study, typically this was 6 weeks, but up to 11 weeks for those also withheld their alpha-1 antitrypsin replacement therapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspirin</title>
          <description>Assessment on aspirin 81mg for 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Assessment on placebo for 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Patient developed syncope during spirometry/</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carrie Pistenmaa</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-342-4162</phone>
      <email>cp2346@&quot;at&quot;cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

